Myotonic Muscular Dystrophies
This article describes the clinical features, pathogenesis, prevalence, diagnosis, and management of myotonic dystrophy type 1 and myotonic dystrophy type 2. RECENT FINDINGS The prevalence of myotonic dystrophy type 1 is better understood than the prevalence of myotonic dystrophy type 2, and new evidence indicates that the risk of cancer is increased in patients with the myotonic dystrophies. In addition, descriptions of the clinical symptoms and relative risks of comorbidities such as cardiac arrhythmias associated with myotonic dystrophy type 1 have been improved. SUMMARY Myotonic dystrophy type 1 and myotonic dystrophy type 2 are both characterized by progressive muscle weakness, early-onset cataracts, and myotonia. However, both disorders have multisystem manifestations that require a comprehensive management plan. While no disease-modifying therapies have yet been identified, advances in therapeutic development have a promising future.
(RMIT University) About 300,000 new cases of ovarian cancer are diagnosed globally each year, with about 60% of women dying within five years after diagnosis. A clinical trial has shown testing for a specific immune biomarker could improve diagnosis.
(American Cancer Society) A new study finds a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure with highest rates in several states on the East and West Coast including Hawaii, but also a few landlocked states, including Utah, Vermont, and Minnesota.
Publication date: Available online 16 February 2020Source: The American Journal of SurgeryAuthor(s): Agnes Ewongwo, Mohammad Hamidi, Zana Alattar, Oluwatosin P. Ayotunde, Hina A. Tiwari, Emad Elquza, Aaron Scott, Kamil Hanna, Valentine NfonsamAbstractIntroductionThe aim of this study was to evaluate patient factors that contribute to increased incidence of early onset rectal cancer and analyze the short-term surgical outcomes of patients undergoing surgery.MethodsA 2-year review (2015–2016) of the ACS-NSQIP included patients with rectal cancer who underwent surgical management. Patients were stratified into early-onset RC (
Publication date: Available online 16 February 2020Source: The American Journal of SurgeryAuthor(s): Chol-Ho Shin, Jong-Lyel Roh, Dong Eun Song, Kyung-Ja Cho, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon KimAbstractBackgroundTumour size and extrathyroidal extension (ETE) may impact papillary thyroid carcinoma (PTC) outcomes. We therefore examined the prognostic value of tumour size and ETE for predicting posttreatment recurrence in PTC patients.MethodsA total of 2,902 patients who underwent thyroidectomy for previously untreated T1–T3 PTC (7th edition American Joint Committee on Cancer) at our tertiary referral center wer...
ConclusionsIn SLNB positive MCC, CLND alone is associated with worse survival compared with treatment with adjuvant radiation or both CLND and adjuvant radiation.
ConclusionSurgery for BCLM is safe and might provide a survival benefit in selected patients but prospective trials are warranted to avoid selection bias.
Publication date: Available online 8 February 2020Source: European Journal of Surgical OncologyAuthor(s): Tibor Kovacs, Isabel Rubio, Christos Markopoulos, Riccardo A. Audisio, Susan Knox, Thorsten Kühn, Robert Mansel, Zoltan Matrai, Francesco Meani, Maurizio Nava, Lynda Wyld, BRESOExecutive summaryThe Breast Surgery theoretical and practical knowledge curriculum comprehensively describes the knowledge and skills expected of a fully trained surgeon practicing in the European Union and European Economic Area (EEA). It forms part of a range of factors that contribute to the delivery of high quality cancer care. It has b...
Refinement of surgery takes the prize for 2020. And many other survival-improving advancements mentioned. Rad onc advances: helped make surgery possible in pancreatic, a non-practice-changing SABR-COMET ("improves survival"?), and CDDP+XRT still a standard in HPV+ H&N cancer.
Authors: Chelvanambi M, Weinstein AM, Storkus WJ Abstract The ability of the immune system to prevent or control the growth of tumor cells is critically dependent on inflammatory processes that lead to the activation, expansion, and recruitment of antitumor effector cells into the tumor microenvironment (TME). These processes are orchestrated by soluble cytokines produced in tissues that alarm local immune surveillance cells (such as dendritic cells, DCs) to mobilize protective antitumor immune populations (B cells, T cells). The interleukin (IL)-36 family of pro-inflammatory cytokines plays an important role ...